1. Home
  2. DERM vs MOLN Comparison

DERM vs MOLN Comparison

Compare DERM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

HOLD

Current Price

$6.35

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.83

Market Cap

154.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DERM
MOLN
Founded
2014
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
154.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DERM
MOLN
Price
$6.35
$3.83
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$12.67
$8.38
AVG Volume (30 Days)
165.8K
5.7K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
N/A
Revenue This Year
$39.72
N/A
Revenue Next Year
$63.24
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
10.20
N/A
52 Week Low
$4.31
$3.41
52 Week High
$9.56
$5.36

Technical Indicators

Market Signals
Indicator
DERM
MOLN
Relative Strength Index (RSI) 43.53 45.08
Support Level $5.80 $3.65
Resistance Level $6.59 $3.96
Average True Range (ATR) 0.36 0.07
MACD -0.12 -0.01
Stochastic Oscillator 25.52 28.28

Price Performance

Historical Comparison
DERM
MOLN

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: